Sharam Danesh, MD
Ophthalmology · Phoenix, AZNPI 1003808809
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,291 of the $6,063 with a category attached, or 70.8%. 21 manufacturers reported payments, led by Eyepoint US, Inc. at 31.2% of the total. Reporting peaked in 2024 at $2,606 and has fallen 67.4% since, to $849 in 2025.
Across 78 payments — averaging $77.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$2K
- Genentech USA, Inc.$678
- Notal Vision, Inc.$519
- AbbVie$396
- Regeneron Healthcare Solutions, Inc.$361
- Dutch Ophthalmic, USA$318
- plus $2K from 15 others
Across 33 payments — averaging $490.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$8K
- Novartis$5K
- Boehringer Ingelheim International GmbH$3K
- Boehringer Ingelheim$389
What the payments were for
- Speaking & faculty fees$5199%
- Travel & lodging$1,24020%
- Food & beverage$4,29171%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 5 | $1,894 |
| Genentech USA, Inc. | 18 | $678 |
| Notal Vision, Inc. | 1 | $519 |
| AbbVie(2 entities) | 12 | $396 |
| Regeneron Healthcare Solutions, Inc. | 9 | $361 |
| Dutch Ophthalmic, USA | 3 | $318 |
| Alcon | 5 | $282 |
| Apellis Pharmaceuticals, Inc. | 4 | $244 |
| Novartis | 2 | $214 |
| Astellas Pharma US Inc | 4 | $205 |
| Eyevance Pharmaceuticals LLC | 1 | $171 |
| Glaukos Corporation | 1 | $132 |
| Kala Pharmaceuticals, Inc. | 1 | $122 |
| F. Hoffmann-la Roche AG | 1 | $112 |
| Genentech, Inc. | 1 | $102 |
| Carl Zeiss Meditec USA, Inc. | 2 | $93 |
| Coherus Oncology, Inc. | 3 | $80 |
| Heidelberg Engineering, Inc. | 1 | $68 |
| Bausch & Lomb Americas Inc. | 2 | $35 |
| LKC Technologies, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYP-1901$1,894
- VABYSMO$252
- Flarex$171
- OZURDEX$135
- iDoseTR$132
- INVELTYS$122
- Izervay$121
- EYLEA HD$121
- EVA, combined machine$120
- TISSUEBLUE$120
- EVA Ophthalmic Surgical System$118
- Syfovre$114
- Constellation$109
- SUSVIMO$102
How this compares
$6,063 in reported general payments places this provider in the 80th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 265 | $13,513 |
| LumiganBimatoprost | 13 | $3,619 |
| Atropine Sulfate | 140 | $3,186 |
| Ofloxacin | 175 | $1,827 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 58 | $913 |
| Latanoprost | 44 | $301 |
| Timolol Maleate | 16 | $182 |
| Brimonidine Tartrate | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $396 | $3,61913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Phoenix
- Pravin DugelPhoenix$176K
- Nishi ShahPhoenix$92K
- Karim JamalPhoenix$72K
- Benjamin HellerPhoenix$41K
- Neal PalejwalaPhoenix$33K
- Joshua DuncanPhoenix$30K
- Sachin MehtaPhoenix$23K
- Daniel ChurginPhoenix$15K
- John CasonPhoenix$14K
- Sujit IttyPhoenix$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.